Innate expands collaborative network beyond oncology with Takeda ADC deal

03 Apr 2023
firstwordpharma.com
License out/inPhase 2ADC
Innate Pharma announced Monday that Takeda will pay it $5 million upfront as part of an exclusive licensing agreement focused on antibody drug conjugates (ADCs). The deal could be worth up to $410 million if future development, regulatory and commercial milestones are met, said Innate.
The agreement provides Takeda exclusive global rights to research and develop a number of ADCs using a panel of Innate antibodies against an undisclosed target. The primary therapeutic focus of the collaboration will be Celiac disease - an indication Takeda is also targeting via a deal with Zedira to co-develop the Phase II small molecule agent ZED1227/TAK-227 announced in October.
Innate has four active partnerships with other large-cap pharmaceutical companies, focused on monoclonal and multi-specific antibodies. This includes a natural killer (NK) cell engager collaboration with Sanofi that was initiated in 2016 and expanded late last year to include development of new therapeutics for the treatment of solid tumours.
The Takeda deal is therefore notable on two fronts: “it expands the application of Innate’s science beyond our oncology focus and demonstrates how our antibody engineering expertise can play a major role in developing ADC formats,” said
Yannis Morel, executive vice president of product portfolio strategy & business development at Innate.
“We are thrilled to be working with Takeda, a company which has been very successful in developing new drugs across multiple therapeutic areas,” added Morel. Innate shares rose 14% in pre-market trading in response to the announcement.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.